Australia markets closed

AbCellera Biologics Inc. (ABCL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
7.90+0.40 (+5.33%)
At close: 04:00PM EDT
7.65 -0.25 (-3.16%)
After hours: 05:29PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close7.50
Open7.58
Bid7.65 x 4000
Ask7.89 x 4000
Day's range7.45 - 7.99
52-week range5.42 - 27.60
Volume2,135,107
Avg. volume1,753,588
Market cap2.248B
Beta (5Y monthly)N/A
PE ratio (TTM)12.32
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Simply Wall St.

    Analysts Just Shipped A Massive Upgrade To Their AbCellera Biologics Inc. (NASDAQ:ABCL) Estimates

    AbCellera Biologics Inc. ( NASDAQ:ABCL ) shareholders will have a reason to smile today, with the analysts making...

  • Motley Fool

    Why AbCellera Biologics Is 10% Lower Today

    Shares of contract drug developer AbCellera Biologics (NASDAQ: ABCL) are down 10% as of 12:04 p.m. ET today, according to data from S&P Global Market Intelligence, following Piper Sandler's lowered price target despite a seemingly strong earnings report. For the three-month stretch ending March 31, biopharma outfit AbCellera Biologics turned $316.6 million worth of revenue into earnings of $0.54 per share. While AbCellera Biologics' CEO Carl Hansen is unsurprisingly optimistic about the future, that's a future in which the drugs' combined revenue contribution could fade -- significantly.

  • Zacks

    AbCellera Biologics Inc. (ABCL) Beats Q1 Earnings and Revenue Estimates

    AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of 14.89% and 22.15%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?